PREDICTIVE ONCOLOGY INC (POAI) Stock News
NASDAQ:POAI - Nasdaq - US74039M3097 - Common Stock - Currency: USD
POAI Latest News, Press Relases and Analysis
Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs
Renovaro Provides Update to Definitive Agreement with Predictive Oncology
Mentions: RENB
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update
Company continues to progress toward the signing of a definitive merger agreement with Renovaro
What's Going On With Predictive Oncology Shares Tuesday?
Predictive Oncology shares are trading higher on Tuesday after the company announced it developed predictive models to target various cancer types.
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update
Company continues to progress toward the signing of a definitive merger agreement with Renovaro...
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary
Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan ...
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries
Deal positions STREAMWAY® Systems with an established market leader to drive accelerating growth Transaction allows Predictive Oncology to be highly...
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries
Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology
Mentions: RENB
Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences
Predictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business...
Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences
Mentions: RENB
Predictive Oncology Closes Registered Direct Offering
PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven...
Predictive Oncology Closes Registered Direct Offering
Predictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven...
Predictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing
Company successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types Creates...
Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing
Predictive Oncology Partners with Switzerland-Based Tecan Group Ltd. to Expand High-Throughput Drug Screening to Include Human Tumor Spheroids Using Automated Imaging and 3D Analysis
Study used Predictive Oncology’s vast biobank of cryopreserved live cell tumor specimens for the production and testing of primary patient tumor spheroids ...
Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay
Initial plans target European clinical trials while providing standard testing to clinicians for individual patients There are an estimated 250,000...
Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay
